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Abstract
Background: Variable selection is an important step in building a multivariate regression model for which several methods
and statistical packages are available. A comprehensive approach for variable selection in complex multivariate regression
analyses within HIV cohorts is explored by utilizing both epidemiological and biostatistical procedures.
Methods: Three different methods for variable selection were illustrated in a study comparing survival time between
subjects in the Department of Defense’s National History Study and the Atlanta Veterans Affairs Medical Center’s HIV Atlanta
VA Cohort Study. The first two methods were stepwise selection procedures, based either on significance tests (Score test),
or on information theory (Akaike Information Criterion), while the third method employed a Bayesian argument (Bayesian
Model Averaging).
Results: All three methods resulted in a similar parsimonious survival model. Three of the covariates previously used in the
multivariate model were not included in the final model suggested by the three approaches. When comparing the
parsimonious model to the previously published model, there was evidence of less variance in the main survival estimates.
Conclusions: The variable selection approaches considered in this study allowed building a model based on significance
tests, on an information criterion, and on averaging models using their posterior probabilities. A parsimonious model that
balanced these three approaches was found to provide a better fit than the previously reported model.
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Introduction
The methods commonly used in selecting variables for
multivariate models can be overshadowed with objective statistical
tests while others, in contrast, grant several subjective decisions to
the researcher. There are risks associated with methods that rely
too heavily on either objectivity or subjectivity. Most notably for
the latter is the concept of researcher bias, which is a process in
which the researcher influences the results of an analysis by forcing
certain variables into or out of regression models typically based
upon associations found in previous studies or logic determined by
causal pathways [1]. For example, statistical tools, such as stepwise
regression and collinearity diagnostics, could suggest a variable be
dropped from further analysis in a multivariate model, but the
researcher may decide to ignore the suggestion and force the
variable into the model. Researcher bias has the ability to impact
the accuracy and precision of conclusions output from data
analyses.
Conversely, some variable selection processes allow for very
little, if any, influence on which variables are kept in or dropped
from multivariate analyses. Such processes include using statistical
significance tests (e.g., Wald) in a stepwise fashion [2,3], in which
variables are selected and/or deleted from an analysis using a pre-
specified significance level (p-value). In essence, the researcher
inputs all variables of interest (which may already have some
associated researcher bias) into a statistical software program, and
runs a stepwise selection process. As a result, the computer
program outputs a model that only includes variables that are
statistically significant at the pre-specified significance level. There
are many theoretical reasons why this approach may perform
poorly in selecting potential confounders [4–10]. In this case, some
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subjective influence over which variables are selected may be
preferred.
While some researchers may opt to utilize only one method in
their analyses, there seems to be an underutilized complementary
nature between objective statistics and subjective decisions when
determining which multivariate model is the best representation of
the data. It has been shown that there exists an inverse relationship
between having too many or too few variables in a model; while
the former results in high variance or uncertainty, the latter results
in more bias [11], or equivalently, inflated Type II error versus
inflated Type I error. Thus, a simplistic and parsimonious model
that fits the data well is preferred.
In this investigation, data were made available by both the
Department of Defense (DoD) and the Department of Veterans
Affairs (VA) in order to further examine a multivariate model (the
‘‘full’’ model) that has previously been published [12]. The goal of
the present analysis was to compare time to all-cause mortality and
clinical outcomes associated with HIV treatment and care between
patients from the HIV Atlanta VA Cohort Study (HAVACS) and
the US Military HIV Natural History Study (NHS) cohort,
adjusted for possible confounders. Here we detail how using a
mixture of commonly used hypothesis-testing statistics concur-
rently with information-theory approaches for model building can
facilitate the detection of a preferred, parsimonious model.
Alternatively, a Bayesian approach that combines several possible
models is also described and compared to the other two
approaches.
Methods
Ethics Statement
The NHS cohort has been approved by the Institutional Review
Board (IRB) centrally (Uniformed Services University of the
Health Sciences, Bethesda, MD) and at each participating center
(Walter Reed National Military Medical Center, Bethesda, MD;
Naval Medical Center, Portsmouth, VA; San Antonio Military
Medical Center, TX; Naval Medical Center, San Diego, CA; and
Tripler Army Medical Center, Honolulu, HI). Written consent
was obtained from each patient. The HAVACS cohort has been
approved by Emory University’s IRB and the Atlanta VA Medical
Center Research and Development Committee. The HAVACS
cohort does not require patients’ written consent as it has an IRB-
approved waiver of consent.
Study Participants
Data were collected from two cohorts: the HAVACS and the
NHS. The NHS has enrolled over 5000 beneficiaries since 1986
into a prospective, multicenter observational study of HIV-
infected active duty military personnel and other military
beneficiaries living with HIV. The NHS cohort characteristics
have been previously described [13]. The HAVACS includes all
HIV-positive veterans seen for care at the Atlanta VA Medical
Center since 1982 (n.3900). The cohort characteristics of
HAVACS have been previously described [14]. Data are
prospectively collected for both cohorts and are used for clinical
care and research purposes.
Patients in both cohorts were eligible for inclusion in this
analysis if they had an HIV diagnosis and began highly active
antiretroviral therapy (HAART) treatment between January 1,
1996 and June 30, 2010. A total of 1199 NHS patients and 1065
HAVACS patients were followed from their recorded HAART
initiation (HI) date through all-cause mortality or the date of last
data entry. Separate internal analyses have determined that only
43 of the total .3900 HAVACS patients were in the NHS cohort,
so the effect of any overlap between the patients examined in this
analysis is negligible.
Variable Definitions
A HAART regimen was defined as the use of three or more
antiretroviral medications, one of which has to be a protease
inhibitor (PI), a non-nucleoside reverse transcriptase inhibitor
(NNRTI), an integrase inhibitor, or an entry inhibitor. A
participant’s HI date was the date of the first HAART regimen
that lasted greater than one month, utilizing an intention to treat
format. Information regarding the participant’s age at HI, sex,
race, year of HIV diagnosis, time from HIV diagnosis to HI, viral
load and CD4 count at HI (within three months prior to HAART
start date), history of chronic hepatitis B and C co-infection, and
previous AIDS-defining illness (ADI) excluding CD4,200, and
previous ARV use (mono or dual NRTI) were also analyzed.
There were no time-updated variables utilized in these analyses.
Statistical Analysis for Full Model
Potential covariates were selected based on previous literature
regarding influences on survival of patients living with HIV in the
presence of HAART [15]. Causal diagrams guided by literature
were also drawn to ensure all selected variables would, in theory,
reduce bias rather than induce bias in the analysis [10,16]. The
covariates were then screened using bivariate analyses and
dropped from further inclusion in multivariate models if their
crude association’s p-value with the outcomes were greater than
0.5. Using an epidemiological modeling approach [16,17], all the
remaining variables and their interactions with the study’s
exposure were combined in a multivariate model (the ‘‘global’’
model) and assessed for collinearity. Using the concept of
hierarchically well-formulated models [16], the interaction terms
were first assessed for elimination from the model using a
likelihood ratio test for significance. The non-interaction, con-
founding terms were then assessed utilizing the change-in-estimate
approach [4–7,9,10]. This approach is similar to a backwards
selection procedure, and a variable was kept in the multivariate
model if its exclusion resulted in an ‘‘important’’ change to the
main exposure variable’s coefficient estimate. A 10% change cut-
off was deemed ‘‘important’’ in this analysis. Covariates that
remained after these procedures were utilized throughout all
analyses.
Kaplan-Meier curves and Cox proportional hazards models
were fitted to investigate time from HI to all-cause mortality by
cohort. Specific to survival analysis, the proportional hazards (PH)
assumptions were gauged for each covariate utilizing a consensus
of three different approaches: graphical, goodness of fit, and
extended Cox modeling [17,18]. All covariates of interest satisfied
the PH assumption. Thus, we can assume that the model including
all remaining covariates (the previously published ‘‘full’’ model), or
any subset of covariates, fit the data [19].
Statistical Analysis for Parsimonious Model
The Score test [20] is an hypothesis-testing statistic that is
similar to commonly used likelihood ratio tests and Wald tests. All
three are equivalent in large samples [21]. The Score statistic is
less computational (requiring only evaluations under the null), and
can be used as the basis for eliminating or including variables in
such models. It is important to note that only nested models can be
compared under this approach.
The Akaike Information Criterion (AIC) provides a practical
and versatile way to identify a parsimonious model from a set of
competing final models, by adding a penalty term proportional to
the number of parameters in the model. This penalty term guards
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against overfitting. The AIC procedure yields an objective
mathematical tool to determine parsimony in model construction
and is free of subjective judgments [22]. Based on a penalized
likelihood, the AIC allows comparison of non-nested models as
well. Its benefits have been extensively described, particularly in
the context of ecological and genetic study designs [23–28];
however, AIC procedures are applicable to other research topics,
such as survival of patients living with HIV [29]. The AIC value
was manipulated into two other related statistics; Akaike weights
(wi) and evidence ratios (ER) [30]. An Akaike weight is found by
taking the proportion of the exponentiated AIC differences
between model i and the model with the smallest AIC value to
the sum of all these differences in all K subset models:
wi~
exp ({(AICi{min (AIC))=2)
PK
k~1
exp ({(AICi{min (AIC))=2)
ð1Þ
The resulting value indicates the probability that the chosen i
model is the best to represent that data among the whole set of K
candidate models (those that were used when calculating the
denominator in equation 1 above).
Evidence ratios are a small extension to Akaike weights – it
directly compares the weights of two models i and j:
ER~
wj
wi
ð2Þ
The yielded value depicts the likelihood that model j is better or
worse than model i to best represent the data given the two models
selected.
An important remark regarding the previous approaches is that
they are two-step procedures: first select a model (variable
selection), and second perform statistical tests given (conditional
on) the selected model being correct. This approach underesti-
mates the variability in the data, by ignoring the uncertainty in the
selected models. Moreover, in practice, two models can fit the data
Figure 1. Comparing Subset Models to a Full Model in Order to Detect a Potential Parsimonious Model. Top panel title: AIC Weights
and Evidence Ratios for Stepwise Selections of Covariates Into a Full Model, Based on AIC Values. Bottom panel title: Score and AIC Values for
Stepwise Selections of Covariates Into a Full Model, Based on Score Values. Note: Areas shaded to the right of the circle-dotted line denotes variables
that were included in the full model but deemed unnecessary for a parsimonious model.
doi:10.1371/journal.pone.0087352.g001
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equally well but provide different estimated effect sizes [31].
Bayesian model averaging addresses these issues in a Bayesian
context. Several models are considered, and the posterior
distribution of the quantity of interest is the average of the
posterior distributions under each model considered, weighted by
their posterior model probabilities [32]. More specifically, given
the data D, the posterior distribution of the parameter of interest b
is given by
P(bjD)~
XK
i~1
P(bjMi,D).P(MijD) ð3Þ
Where M1,…MK are the models considered, and P(Mi|D) is the
posterior probability of the model Mi given the data.
In a survival data context, several Cox models M1,…MK are
fitted, and b is the hazard ratio of interest [33]. The best K models
in terms of the Bayesian information criterion (BIC) are selected
using an efficient leaps and bound algorithm [34], and the
posterior hazard ratio is estimated. One can also estimate a
conditional posterior hazard ratio (HR), conditional on that
particular covariate be included in all K models considered. The
conditional HRs for each variable are obtained after averaging the
posterior HRs only for the models containing that particular
variable, and therefore are more likely to have nonzero HRs, while
the unconditional HRs are obtained by averaging over all top K
selected models. The result is that unconditional HRs are expected
to be closer to zero than conditional HRs. We emphasize the
conditional approach to Bayesian model averaging because it
strikes a balance between an unconditional approach and stepwise
selection – it averages over the posterior models that include the
particular variable, allowing for the other variables to be included
or not in the model.
Analyses were conducted with SAS 9.2 (SAS, Cary, NC, USA)
and R (R Development Core Team (2008). R: A language and
environment for statistical computing. R Foundation for Statistical
Computing, Vienna, Austria). SAS and R code can be found as
Figure S1.
Results
Hypothesis-Testing Approach
Twelve covariates were initially selected from the databases to
be included in the modeling process. These potential confounders
were selected due to their influences on the survival of patients
living with HIV in the presence of ARV therapy [35]. After
bivariate analyses, one variable, year of HIV diagnosis, was
dropped. The global model was constructed to include the 11
remaining covariates and their interactions with the main
exposure variable, which denotes the cohort of each patient. After
collinearity assessments and backwards elimination processes, all
interaction terms were dropped from the list of potential
covariates. The change-in-estimate procedure detected subset
models; however, none of these models performed better than a
model including all remaining covariates with regards to the
precision of the exposure’s effect. Thus, the full model included
only 12 covariates, one of which was the main exposure.
Information-Theory Approach
Instead of halting the variable selection process, Score tests and
AIC comparisons were then implemented on the full model to
determine if a better fitting and more parsimonious model existed.
All 12 variables were cumulatively added to a multivariate model
in two fashions: by the largest incremental change in AIC value
and by the largest incremental change in Score statistic. Both of
these statistics detected the existence of a parsimonious model; in
fact, the same parsimonious model was found using both methods
to add covariates to the model (Figure 1).
Akaike weights and ERs were computed for each subset model
and found that a parsimonious model that did not include race,
time from HIV diagnosis to HI, and previous ADI was 10.9 times
more likely than the full model to be the best model to represent
the data, given the chosen set of subset models. The Score tests
similarly suggested that this parsimonious model was the best
model.
The full model controlling for all 12 covariates concluded that
patients in NHS were 57% less likely to die during follow-up
compared to patients in HAVACS (HR 0.43, 95% CI 0.27, 0.70;
p = 0.0005). However, the parsimonious model that dropped race,
previous ADI, and time from HIV diagnosis to HI, concluded that
NHS patients were 58% less likely to die during follow-up
compared to patients in HAVACS (HR 0.42, 95% CI 0.27, 0.65;
p = 0.0001). The minimal change in the main effect estimate
between the models can be attributed to the lack of information
the three variables (race, previous ADI, and time from HIV
diagnosis to HI) brought to the full model. In fact, after exploring
the distributions of these three variables, there was evidence for a
lack of racial diversity in the HAVACS cohort (78.8% were
African-American/Black), a lack of previous ADI events in the
NHS cohort (3.4%), and there were similar time periods between
HIV diagnosis and HI in the entire sample (median: 4.7 months in
the NHS; 5.0 months in the HAVACS, p= 0.6774).
Bayesian Model Averaging Approach
The model with the highest approximate posterior probability
was a model including cohort, age, CD4, and hepatitis C. This
model represented only 11.3% of the total posterior probability,
while the top five models had a cumulative posterior probability of
42.2%, indicating a moderately high model uncertainty. Figure 2
Figure 2. Models Considered by Bayesian Model Averaging, in
Order of Posterior Probability. Variables Positively (Negatively)
Associated With Outcome are in Grey (Black).
doi:10.1371/journal.pone.0087352.g002
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depicts the top 44 models (columns) in terms of their posterior
probability that were used for model averaging (K=44). Variables
(rows) positively correlated with the outcome appear in black,
while those negatively correlated with the outcome appear in grey.
Column width for each column (model) is proportional to the
posterior probability of that model.
Table 1 also presents the posterior hazard ratios and the
conditional hazard ratios, conditional on the corresponding
variable being included in the model. The posterior probability
is the probability that the corresponding variable is correlated with
the outcome. There is close agreement between the AIC-based
variable selection approach and the Bayesian model averaging.
The variables race, time from HIV diagnosis to HI, and previous
ADI were dropped from the parsimonious model and similarly
had low posterior probabilities (4.3%, 3.2%, and 3.4%, respec-
tively). The only discrepancy is the variable initial HAART
regimen, which was not dropped in the AIC approach, but has a
zero posterior probability under the Bayesian approach. It is of
note that within the AIC approach, the difference in AIC values
for a model including initial HAART regimen and one without the
variable was merely 0.46 (1773.57 vs. 1774.04, respectively).
Regarding the selected variables, a general remark is that the
confidence intervals in the parsimonious model are usually tighter,
due to decreased uncertainty introduced by the excluded variables.
The effects of hepatitis B and C and previous ARV use appear
more impactful in the AIC-based approach relative to the
Bayesian approach (HR 1.86, 1.63, and 1.33 versus HR 1.33,
1.24, and 1.08, respectively). Interestingly, the two approaches
give very similar results conditional on the variables being included
in the model. Thus, the biostatistical tools used in these analyses
detected problematic variables and removed them to form a better
fitting model that collinearity tests alone could not identify.
Otherwise, the conclusions that the full model suggests are similar
to those of the parsimonious model, thus confirming the AIC’s
detection of a model that results in minimal information loss.
Table 1. Comparison of All-Cause Mortality Cox Regression Models Between NHS and HAVACS Patients Based on Three
Approaches: Hypothesis-Testing, Information-Theory, And Bayesian Model Averaging, 1996 – 2010, n = 1,727.
Hypothesis-testing Information-theory Bayesian model averaging
"Full" model "Parsimonious" model Posterior Conditional posterior
Covariate HR 95% CI HR 95% CI
Selected
(%) HR 95% CI HR 95% CI
Cohort, NHS vs. HAVACS 0.43 0.27, 0.70 0.42 0.27, 0.65 100.0% 0.39 0.25, 0.61 0.38 0.25, 0.61
Demographics
Age at HAART initiation 1.06 1.04, 1.08 1.06 1.04, 1.08 100.0% 1.06 1.04, 1.08 1.06 1.04, 1.08
Sex, female vs. male 2.64 0.64, 10.80 2.58 0.63, 10.55 14.1% 1.14 0.50, 2.64 2.60 0.64, 10.59
Race, AA vs. other 1.20 0.80, 1.79 – 4.3% 1.00 0.91, 1.11 1.16 0.79, 1.74
Medical history (prior to HAART
initiation)
HIV diagnosis to HAART initiation 1.00 0.99, 1.01 – 3.2% 1.00 1.00, 1.00 1.00 0.99, 1.01
Viral load at HAART initiation,
log copies/mL
9.8%
,2.60 0.46 0.19, 1.15 0.47 0.19, 1.15 0.93 0.55, 1.57 0.46 0.08, 2.87
2.60–3.99 1.46 0.91, 2.33 1.46 0.91, 2.33 1.04 1.01, 1.36 1.48 0.27, 8.25
$4.00 ref ref ref ref
CD4 at HAART initiation, cells/mL 85.0%
,200 1.28 0.79, 2.07 1.30 0.82, 2.06 1.36 0.84, 2.20 1.43 0.45, 4.60
200–349 0.60 0.34, 1.03 0.61 0.35, 1.05 0.69 0.38, 1.24 0.64 0.19, 2.26
$350 ref ref ref ref
Previous AIDS-defining illnessa 0.95 0.62, 1.43 – 3.4% 1.00 0.92, 1.08 0.92 0.61, 1.39
Chronic hepatitis B co-infection 1.89 1.10, 3.25 1.86 1.09, 3.20 44.5% 1.33 0.65, 2.73 1.90 1.10, 3.26
Hepatitis C co-infection 1.60 1.08, 2.38 1.63 1.12, 2.39 49.0% 1.24 0.75, 2.06 1.55 1.06, 3.26
Previous antiretroviral use 1.40 0.95, 2.07 1.33 0.93, 1.92 23.6% 1.08 0.78, 1.49 1.38 0.96, 1.98
Initial HAART regimen 0.0%
Non-nucleoside reverse transcriptase
inhibitor
ref ref
Boosted protease inhibitor 1.78 1.10, 2.86 1.74 1.08, 2.81
Unboosted protease inhibitor 1.28 0.86, 1.90 1.29 0.87, 1.91
Other 0.72 0.25, 2.01 0.71 0.25, 1.99
Abbreviations: AA - African -American/Black ; AIDS – acquired immune deficiency syndrome; CD4 – cluster of differentiation 4; CI – confidence interval; HAART - Highly
Active Antiretroviral Therapy; HAVACS - HIV Atlanta VA Cohort Study; HR – hazard ratio; NHS - US Military HIV Natural History Study; ref – referent group.
Notes: Bold hazard ratios and 95% confidence intervals are significant at the P,0.05 level.
a1993 definition, exclusive of CD4,200.
doi:10.1371/journal.pone.0087352.t001
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Discussion
The AIC has been reported to be a better tool in the field of
model selection than traditional hypothesis-testing [22,28]. In
certain instances, stepwise variable selection based on hypothesis-
testing may lead to different final models, depending on the order
the variables are considered (e.g., forward, backward). The
information-theoretic approach utilized by the AIC statistic often
yields consistent results and does not depend on the order of which
variables are selected [19,28,36]. In this example, an information-
theoretic approach was balanced with a limited use of hypothesis-
testing, which resulted in a parsimonious model that was nearly 11
times more likely than the full model to be the best choice. The
utilization of AIC values or Score tests resulted in the same
parsimonious model, which suggests that any additional explora-
tion for a better-fitting model to only traditional hypothesis-testing
may result in less variance in its estimates. The variables dropped
from the full model to create the parsimonious model were chosen
to be included in the initial multivariate analyses due to their cited
influences on the survival of patients living with HIV while on
HAART; nevertheless, due to the unique characteristics of the
cohorts used in this analysis, they did not necessarily need to be
controlled for in a model. Furthermore, the excluded variables
were already being controlled for indirectly; in particular, previous
AIDS diagnosis was partly captured by the CD4 count at HAART
initiation variable (i.e., AIDS is usually associated with lower
CD4).
Stepwise methods, such as the AIC approach used in this
analysis, are two-stage procedures. First, a model that shows
evidence of fit is selected, and then, conditional on this model
being correct, one estimates the hazard ratios associated with the
variables selected, and significance tests are performed. The
Bayesian approach provides an alternative paradigm in which
several models are considered at the same time, and the posterior
parameters are simply weighted averages of the estimates from
each model, with weights given by the posterior probability of each
model given the data. One benefit of this approach is that it
provides a coherent framework for distinguishing between lack of
power to detect a significant effect, and a lack of correlation
between the covariate and the outcome [33].
These analyses emphasize that while no single model is perfect,
some are more useful than others. Similarly, these analyses suggest
that only using the common hypothesis-testing methods could
result in a model including variables that introduce excessive
variance in the estimates. The goal is to have an expansive and
rich ‘‘toolbox’’ of methods than can guide a researcher to a more
useful model. When multiple approaches lead to the same or
similar results, the conclusion is considerably strengthened and
ultimately variance is diminished. The statistical tools used in this
analysis are also applicable to other regression-type models.
Further research should be employed on alternative datasets and
data types to explore situations in which this multiple-approach
method does not result in the same or similar final models as well
as models aiming to make accurate predictions of an outcome.
Conclusions
Given the advent of methodological developments and the
availability of statistical software, exploring several options for
variable selection may prove beneficial when building complex
multivariate models. Our analyses demonstrated such an amal-
gamation that resulted in a better-fitting, parsimonious multivar-
iate model than what would have been reported by utilizing only
one approach. We propose the usage of the same or similar robust,
multi-approach methodology in an attempt to detect a preferred
parsimonious model in other analyses.
Supporting Information
Figure S1 SAS and R code.
(PDF)
Author Contributions
Conceived and designed the experiments: CR VM. Performed the
experiments: CR IB. Analyzed the data: CR IB. Contributed reagents/
materials/analysis tools: DR BA. Wrote the paper: CR IB JG DR BA VM.
References
1. Johnson RB (1997) Examining the validity structure of qualitative research.
Educat 118: 282–292.
2. SAS Institute Inc (2012) SAS Guide for Personal Computers. Cary, NC: SAS
Institute Inc.
3. Greenland S (1989) Modeling and Variable Selection in Epidemiologic Analysis.
Am J Public Health 79: 340–349.
4. Breslow N, Day N (1980) Statistical Methods in Cancer Research. I: The
Analysis of Case-Control Studies. Lyon: IARC.
5. Dales LG, Ury HK (1978) An Improper Use of Statistical Significance Testing in
Studying Covariables. Int J Epidemiol 7: 373–375.
6. Greenland S, Neutra R (1980) Control of Confounding in the Assessment of
Medical Technology. Int J Epidemiol 9: 361–367.
7. Miettinen OS (1976) Stratification by a Multivariate Confounder Score. Am J
Epidemiol 104: 609–620.
8. Robins JM, Greenland S (1986) The Role of Model Selection in Causal
Inference From Nonexperimental Data. Am J Epidemiol 123: 392–402.
9. Rothman KJ (1977) Epidemiologic Methods in Clinical Trials. Cancer 39:
1771–1775.
10. Rothman KJ, Greenland S, Lash TL (2008) Modern Epidemiology. Philadel-
phia, PA: Lippincott Williams & Wilkins.
11. Burnham KP, Anderson DR (2001) Kullback-Leibler information as a basis for
strong inference in ecologic studies. Wildl Res 28: 111–119.
12. Guest JL, Weintrob AC, Rimland D, Rentsch C, Bradley WP, et al. (2013) A
Comparison of HAART Outcomes between the US Military HIV Natural
History Study (NHS) and HIV Atlanta Veterans Affairs Cohort Study
(HAVACS). PLoS ONE 8: e62273.
13. Sweeney S, Obure CD, Maier CB, Greener R, Dehne K, et al. (2012) Costs and
efficiency of integrating HIV/AIDS services with other health services: a
systematic review of evidence and experience. Sex Transm Infect 88: 85–99.
14. Weintrob AC, Grandits GA, Agan BK, Ganesan A, Landrum ML, et al. (2009)
Virologic Response Differences Between African Americans and European
Americans Initiating Highly Active Antiretroviral Therapy With Equal Access to
Care. J Acquir Immune Defic Syndr 52: 574–580.
15. Anderson K, Guest J, Rimland D (2004) Hepatitis C Virus Coinfection Increases
Mortality in HIV-Infected Patients in the Highly Active Antiretroviral Therapy
Era: Data from the HIV Atlanta VA Cohort Study. Clin Infect Dis 39: 1507–
1513.
16. Kleinbaum DG, Klein M (2010) Logistic Regression: A Self-Learning Text. New
York, NY: Springer.
17. Kleinbaum DG, Klein M (2005) Survival Analysis: A Self-Learning Text. New
York, NY: Springer.
18. Therneau TM, Grambsch PM (2000) Modeling Survival Data: Extending the
Cox Model: Springer-Verlag.
19. Anderson DR, Burnham KP, Thompson WL (2000) Null Hypothesis Testing:
Problems, Prevalence, and an Alternative. J Wildl Manag 64: 912–923.
20. Kleinbaum DG, Kupper LL, Chambless LE (1982) Logistic regression analysis
of epidemiologic data: theory and practice. Commun Stat - Theory and
Methods 11: 485–547.
21. Lehmann E (2009) Elements of Large Sample Theory: Springer.
22. Akaike H (1974) A new look at the statistical model identification. IEEE
Transact Autom Contr 19: 716–723.
23. Anderson DR, Burnham KP, White G (1994) AIC Model Selection in
Overdispersed Capture-Recapture Data. Ecol 75: 1780–1793.
24. Bozdogan H (1987) Model selection and Akaike’s information criterion (AIC):
the general theory and its analytical extensions. Psychometrika 52: 345–370.
25. Burnham KP, Anderson DR, Huyvaert KP (2011) AIC model selection and
multimodel inference in behavioral ecology: some background, observations,
and comparisons. Behav Ecol Sociobiol 65: 23–35.
26. Huggins RM (1991) Some practical aspects of a conditional likelihood approach
to capture experiments. Biometrics 47: 725–732.
Variable Selection in HIV Cohort Analyses
PLOS ONE | www.plosone.org 6 January 2014 | Volume 9 | Issue 1 | e87352
27. Lebreton J-D, Burnham KP, Clobert J, Anderson DR (1992) Modeling Survival
and Testing Biological Hypotheses Using Marked Animals: A Unified Approach
with Case Studies. Ecol Monogr 62: 67–118.
28. Posada D, Buckley TR (2004) Model selection and model averaging in
phylogenetics: advantages of akaike information criterion and bayesian
approaches over likelihood ratio tests. Syst Biol 53: 793–808.
29. May M, Royston P, Egger M, Justice AC, Sterne JA (2004) Development and
validation of a prognostic model for survival time data: application to prognosis
of HIV positive patients treated with antiretroviral therapy. Stat Med 23: 2375–
2398.
30. Wagenmakers E-J, Farrell S (2004) AIC model selection using Akaike weights.
Psychonom Bull Rev 11: 192–196.
31. Regal RR, Hook EB (1991) The Effects of Model Selection on Confidence
Intervals for the Size of a Closed Population. Stat Med 10: 717–721.
32. Hoeting JA, Madigan D, Raftery AE, Volinsky CT (1999) Bayesian Model
Averaging: A Tutorial. Statist Sci 14: 382–417.
33. Volinsky CT, Madigan D, Raftery AE, Kronmal RA (1997) Bayesian Model
Averaging in Proportional Hazard Models: Assessing the Risk of a Stroke. Appl
Statistics 46: 433–448.
34. Furnival GM, Wilson RW (1974) Regressions by Leaps and Bounds.
Technometrics 16: 499–511.
35. Marconi VC, Grandits GA, Weintrob AC, Chun H, Landrum ML, et al. (2010)
Outcomes of highly active antiretroviral therapy in the context of universal
access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res
Ther 7: 14.
36. Burnham KP, Anderson DR (2002) Model selection and multimodel inference: a
practical information-theoretic approach. New York, NY: Springer-Verlag New
York, Inc.
Variable Selection in HIV Cohort Analyses
PLOS ONE | www.plosone.org 7 January 2014 | Volume 9 | Issue 1 | e87352
